SG11201505858VA - A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease - Google Patents

A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease

Info

Publication number
SG11201505858VA
SG11201505858VA SG11201505858VA SG11201505858VA SG11201505858VA SG 11201505858V A SG11201505858V A SG 11201505858VA SG 11201505858V A SG11201505858V A SG 11201505858VA SG 11201505858V A SG11201505858V A SG 11201505858VA SG 11201505858V A SG11201505858V A SG 11201505858VA
Authority
SG
Singapore
Prior art keywords
infectious disease
cell therapy
chimeric receptor
against cancer
therapy against
Prior art date
Application number
SG11201505858VA
Inventor
Dario Campana
Tu-Hsiang Chang
Original Assignee
St Jude Childrens Res Hospital
Univ Singapore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by St Jude Childrens Res Hospital, Univ Singapore filed Critical St Jude Childrens Res Hospital
Publication of SG11201505858VA publication Critical patent/SG11201505858VA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4613—Natural-killer cells [NK or NK-T]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464429—Molecules with a "CD" designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0081—Purging biological preparations of unwanted cells
    • C12N5/0087—Purging against subsets of blood cells, e.g. purging alloreactive T cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
SG11201505858VA 2013-01-28 2014-01-28 A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease SG11201505858VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361757481P 2013-01-28 2013-01-28
PCT/US2014/013292 WO2014117121A1 (en) 2013-01-28 2014-01-28 A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease

Publications (1)

Publication Number Publication Date
SG11201505858VA true SG11201505858VA (en) 2015-09-29

Family

ID=51228124

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201505858VA SG11201505858VA (en) 2013-01-28 2014-01-28 A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease

Country Status (4)

Country Link
US (8) US9511092B2 (en)
EP (1) EP2948544A4 (en)
SG (1) SG11201505858VA (en)
WO (1) WO2014117121A1 (en)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10332332B2 (en) 2007-12-21 2019-06-25 Cfph, Llc System and method for slot machine game associated with financial market indicators
US8758108B2 (en) 2007-12-21 2014-06-24 Cfph, Llc System and method for slot machine game associated with market line wagers
US11257330B2 (en) 2008-02-15 2022-02-22 Cfph, Llc System and method for providing a baccarat game based on financial market indicators
WO2014117121A1 (en) 2013-01-28 2014-07-31 St. Jude Children's Research Hospital, Inc. A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease
CA2948462A1 (en) 2014-05-15 2015-11-19 National University Of Singapore Modified natural killer cells and uses thereof
GB201501175D0 (en) 2015-01-23 2015-03-11 Univ Oslo Hf A universal T-cell for personalised medicine
US10640570B2 (en) * 2015-01-29 2020-05-05 Regents Of The University Of Minnesota Chimeric antigen receptors, compositions, and methods
US10744157B2 (en) * 2015-03-26 2020-08-18 The Trustees Of Dartmouth College Anti-MICA antigen binding fragments, fusion molecules, cells which express and methods of using
WO2017004252A1 (en) * 2015-06-30 2017-01-05 The Arizona Board Of Regents On Behalf Of The University Of Arizona Redirected cells with mhc chimeric receptors and methods of use in immunotherapy
US10875919B2 (en) 2016-04-26 2020-12-29 Alector Llc Chimeric receptors and methods of use thereof
US11649288B2 (en) 2017-02-07 2023-05-16 Seattle Children's Hospital Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
WO2018160622A1 (en) 2017-02-28 2018-09-07 Endocyte, Inc. Compositions and methods for car t cell therapy
WO2018165913A1 (en) * 2017-03-15 2018-09-20 南京凯地生物科技有限公司 Specific chimeric antigen receptor targeting nkg2dl and car-t cell thereof and use thereof
RU2019128544A (en) 2017-03-27 2021-04-28 Нэшнл Юниверсити Оф Сингапур LINE OF STIMULATING CELLS FOR EX VIVO REPRODUCTION AND ACTIVATION OF NATURAL KILLER CELLS
CN117384929A (en) * 2017-03-27 2024-01-12 新加坡国立大学 Polynucleotide encoding chimeric receptor expressed by cell
EP3612210A4 (en) 2017-04-19 2021-01-27 Board Of Regents, The University Of Texas System Immune cells expressing engineered antigen receptors
EP3720951A1 (en) * 2017-12-05 2020-10-14 Celyad S.A. Compositions and methods for improving persistence of cells for adoptive transfer
CN112218943A (en) 2017-12-05 2021-01-12 塞利亚德股份公司 Killing agents to reduce immune cells expressing NKG 2D-based receptors
WO2019127215A1 (en) * 2017-12-28 2019-07-04 Nanjing Legend Biotech Co., Ltd. Multispecific chimeric receptors comprising an nkg2d domain and methods of use thereof
TW201940182A (en) 2018-01-22 2019-10-16 美商安德賽特公司 Methods of use for CAR T cells
CA3089170A1 (en) * 2018-02-09 2019-08-15 National University Of Singapore Activating chimeric receptors and uses thereof in natural killer cell immunotherapy
JP2021512614A (en) * 2018-02-09 2021-05-20 ナショナル ユニヴァーシティー オブ シンガポール Adhesive receptor constructs and their use in natural killer cell immunotherapy
US20210309713A1 (en) * 2018-04-04 2021-10-07 Daren Biotech Limited Chimeric Antigen Receptor and Method for Treating Cancers
WO2019195541A1 (en) * 2018-04-06 2019-10-10 H. Lee Moffitt Cancer Center And Research Institute Inc. Nkg2d chimeric antigen receptors
WO2020005837A1 (en) * 2018-06-25 2020-01-02 The Trustees Of The University Of Pennsylvania Compositions and methods of nkg2d chimeric antigen receptor t cells for controlling triple-negative breast cancer
EP3850004A4 (en) * 2018-09-13 2022-09-07 Nkarta, Inc. Natural killer cell compositions and immunotherapy methods for treating tumors
JP2022512922A (en) * 2018-11-06 2022-02-07 ワシントン・ユニバーシティ Chimeric antigen receptor memory-like (CARML) NK cells and their production and usage
WO2020160419A1 (en) * 2019-02-01 2020-08-06 The Trustees Of Dartmouth College Signaling platforms for chimeric antigen receptor t cells
CN111544585A (en) * 2019-02-11 2020-08-18 北京卡替医疗技术有限公司 Adjuvant capable of boosting immune cells to expand in vivo
EP3773918A4 (en) 2019-03-05 2022-01-05 Nkarta, Inc. Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy
US20200308248A1 (en) * 2019-03-26 2020-10-01 ST Phi Therapeutics Chimeric Natural Killer Cell Receptors and Method of Using Thereof
CN111363046A (en) * 2020-03-11 2020-07-03 深圳宾德生物技术有限公司 Chimeric antigen receptor targeting NKG2D, chimeric antigen receptor T cell, and preparation method and application thereof
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
AR124414A1 (en) 2020-12-18 2023-03-22 Century Therapeutics Inc CHIMERIC ANTIGEN RECEPTOR SYSTEM WITH ADAPTABLE RECEPTOR SPECIFICITY
GB202110363D0 (en) 2021-07-19 2021-09-01 Celyad S A NKG2D CAR cells expressing IL-18 for adoptive cell therapy
WO2023086642A2 (en) * 2021-11-15 2023-05-19 City Of Hope Engineering or inducing pdgf and/or pdgfr signaling to enhance nk cell therapy
CN116179495A (en) * 2022-11-28 2023-05-30 上海恩凯细胞技术有限公司 Transgenic immune cells and uses thereof
KR20240111378A (en) 2023-01-09 2024-07-17 주식회사 셀젠텍 NKG2D Chimeric Receptor, Transformed Cell Expressing the Same and Its Use for Anti-Cancer

Family Cites Families (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19520729A1 (en) 1995-06-07 1996-12-12 Orpegen Pharma Gmbh Test system for recording the activity of NK cells
EP1003861B1 (en) 1997-08-01 2006-10-04 Schering Corporation Mammalian cell membrane proteins; related reagents
DE69916581T2 (en) 1998-02-02 2004-09-16 The Johns Hopkins University School Of Medicine A UNIVERSAL IMMUNO-MODULATORY CYTOKIN-EXPRESSING CELL LINE IN WAITING. CORRESPONDING COMPOSITIONS AND METHODS OF THEIR PRODUCTION AND USE
DE19813759C1 (en) 1998-03-27 1999-07-15 Gsf Forschungszentrum Umwelt Inducing a natural killer cell immune response ex vivo
AU7954500A (en) 1999-10-21 2001-04-30 Yuji Ohkubo Method of in vitro culture of lymphocytes and gene therapy compositions
JP3619853B2 (en) 1999-11-26 2005-02-16 独立行政法人理化学研究所 Method of growing natural killer cells
JP2002045174A (en) 2000-07-31 2002-02-12 Inst Of Physical & Chemical Res Method for proliferating natural killer cell
EP1578923A4 (en) * 2002-04-22 2009-01-21 Hutchinson Fred Cancer Res Soluble mic polypeptides as markers for diagnosis, prognosis and treatment of cancer and autoimmune diseases or conditions
AU2003270823A1 (en) 2002-09-19 2004-04-08 Johns Hopkins University School Of Medicine Cancer immunotherapy with a viral antigen-defined, immunomodulator-secreting cell vaccine
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
US20130266551A1 (en) 2003-11-05 2013-10-10 St. Jude Children's Research Hospital, Inc. Chimeric receptors with 4-1bb stimulatory signaling domain
US20050113564A1 (en) 2003-11-05 2005-05-26 St. Jude Children's Research Hospital Chimeric receptors with 4-1BB stimulatory signaling domain
WO2006036445A2 (en) * 2004-09-24 2006-04-06 Trustees Of Dartmouth College Chimeric nk receptor and methods for treating cancer
GB0426903D0 (en) 2004-12-08 2005-01-12 Alexis Biotech Ltd Complexes and methods
JP2009513608A (en) 2005-10-28 2009-04-02 ノボ・ノルデイスク・エー／エス Fusion protein that binds effector lymphocytes to target cells
DK2537416T3 (en) 2007-03-30 2015-01-05 Sloan Kettering Inst Cancer Constitutive expression of costimulatory ligands ON adoptively transferred T-LYMPHOCYTES
WO2009117566A1 (en) 2008-03-21 2009-09-24 H. Lee Moffitt Cancer Center And Research Institute, Inc. Chemokine gene-modified cells for cancer immunotherapy
WO2016149264A1 (en) 2015-03-18 2016-09-22 The Johns Hopkins University Compositions and methods for sensitizing cells to trail-induced apoptosis
CN102428173B (en) 2009-03-26 2014-07-30 细胞维护北欧制药公司 Expansion of NK cells
WO2011053321A1 (en) 2009-10-30 2011-05-05 University Of Arkansas For Medical Science Use of autologous effector cells for treatment of multiple myeloma
WO2011053322A1 (en) 2009-10-30 2011-05-05 University Of Arkansas For Medical Science Use of autologous effector cells and antibodies for treatment of multiple myeloma
JP5916718B2 (en) * 2010-06-04 2016-05-11 ビオメリューＢｉｏｍｅｒｉｅｕｘ Method and kit for determining prognosis of colorectal cancer
WO2012002040A1 (en) 2010-07-01 2012-01-05 Semiconductor Energy Laboratory Co., Ltd. Driving method of liquid crystal display device
BR112013000822B1 (en) 2010-07-13 2021-02-23 Anthrogenesis Corporation TWO-STEP IN VITRO METHOD FOR THE PRODUCTION OF A POPULATION OF ACTIVATED NATURAL EXTERMINATOR (NK) PEOPLE
EP2614151B1 (en) 2010-09-08 2019-07-24 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Interleukin 15 as selectable marker for gene transfer in lymphocytes
ES2754394T3 (en) 2010-09-08 2020-04-17 Chemotherapeutisches Forschungsinstitut Georg Speyer Haus Chimeric antigen receptors with an optimized hinge region
CN106963947A (en) 2010-11-22 2017-07-21 伊纳特医药股份有限公司 NK cells adjustment for the treatment of and the method for treating Hematological Malignancies
AU2012308205A1 (en) 2011-09-16 2014-03-13 The Trustees Of The University Of Pennsylvania RNA engineered T cells for the treatment of cancer
WO2013126720A2 (en) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Compositions and methods for the assessment of target cancer cell resistance to car engineered t cell killing
WO2013126726A1 (en) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Double transgenic t cells comprising a car and a tcr and their methods of use
SG11201408697QA (en) 2012-06-28 2015-02-27 Univ Central Florida Res Found Methods and compositions for natural killer cells
EP2872617A4 (en) 2012-07-13 2015-12-09 Univ Pennsylvania Epitope spreading associated with car t-cells
AR092745A1 (en) 2012-10-01 2015-04-29 Univ Pennsylvania COMPOSITIONS THAT INCLUDE AN ANTI-FAP UNION DOMAIN AND METHODS TO MAKE WHITE IN STROMAL CELLS FOR THE TREATMENT OF CANCER
EP2903637B1 (en) 2012-10-02 2019-06-12 Memorial Sloan-Kettering Cancer Center Compositions and methods for immunotherapy
US10786532B2 (en) 2012-10-02 2020-09-29 Versiti Blood Research Institute Foundation, Inc. Method of providing cellular therapy using modified natural killer cells or T lymphocytes
US20150329640A1 (en) 2012-12-20 2015-11-19 Bluebird Bio, Inc. Chimeric antigen receptors and immune cells targeting b cell malignancies
WO2014117121A1 (en) 2013-01-28 2014-07-31 St. Jude Children's Research Hospital, Inc. A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease
PT3613439T (en) 2013-02-15 2021-05-12 Univ California Chimeric antigen receptor and methods of use thereof
MY175869A (en) 2013-02-26 2020-07-14 Memorial Sloan Kettering Cancer Center Compositions and methods for immunotherapy
CA2904369A1 (en) 2013-03-07 2014-09-12 Baylor College Of Medicine Targeting cd138 in cancer
JP2016513458A (en) 2013-03-10 2016-05-16 ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ Chemotherapy resistant immune cells
EP2970426B1 (en) 2013-03-15 2019-08-28 Michael C. Milone Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
MY195733A (en) 2013-03-15 2023-02-08 Memorial Sloan Kettering Cancer Center Compositions and Methods for Immunotherapy
EP3470423B1 (en) 2013-04-17 2021-10-06 Baylor College of Medicine Immunosuppressive tgf-beta signal converter
EP3974520A1 (en) 2013-05-14 2022-03-30 Board of Regents, The University of Texas System Human application of engineered chimeric antigen receptor (car) t-cells
EP3008173B1 (en) 2013-06-10 2021-09-15 Dana-Farber Cancer Institute, Inc. Methods and compositions for reducing immunosupression by tumor cells
KR102245536B1 (en) 2013-07-16 2021-04-28 아크조노벨코팅스인터내셔널비.브이. Intumescent composition
WO2015042661A2 (en) 2013-09-24 2015-04-02 Vayeron Pty Ltd An idler, a method for monitoring a plurality of idlers, and a conveyor system
JP6417413B2 (en) 2013-10-17 2018-11-07 ナショナル ユニヴァーシティー オブ シンガポール Chimeric receptors induce antibody-dependent cytotoxicity against a variety of tumors
CA2929087A1 (en) 2013-10-31 2015-05-07 Fred Hutchinson Cancer Research Center Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
EP3071223B1 (en) 2013-11-21 2021-01-13 UCL Business Ltd Cell
US10239948B2 (en) 2013-12-20 2019-03-26 Cellectis Method of engineering multi-input signal sensitive T cell for immunotherapy
SI3083671T1 (en) 2013-12-20 2021-02-26 Fred Hutchinson Cancer Research Center Tagged chimeric effector molecules and receptors thereof
CN113307880A (en) 2014-01-13 2021-08-27 希望之城公司 Chimeric Antigen Receptors (CARs) having mutations in the Fc spacer region and methods of use thereof
CN106414723A (en) 2014-02-10 2017-02-15 纳维基因股份有限公司 Cell modulation nanocomposition, and methods of use
KR102375998B1 (en) 2014-02-14 2022-03-21 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 Chimeric antigen receptors and methods of making
US20170081411A1 (en) 2014-03-15 2017-03-23 Novartis Ag Regulatable chimeric antigen receptor
GB201405845D0 (en) 2014-04-01 2014-05-14 Ucl Business Plc Signalling system
WO2015154012A1 (en) 2014-04-03 2015-10-08 Memorial Sloan-Kettering Cancer Center Clonogenic natural killer (nk) cell populations and methods of producing and using such populations
KR102021982B1 (en) 2014-04-25 2019-09-18 블루버드 바이오, 인코포레이티드. Mnd promoter chimeric antigen receptors
EP3169773B1 (en) 2014-07-15 2023-07-12 Juno Therapeutics, Inc. Engineered cells for adoptive cell therapy
US10851149B2 (en) 2014-08-14 2020-12-01 The Trustees Of The University Of Pennsylvania Treatment of cancer using GFR α-4 chimeric antigen receptor
WO2016033331A1 (en) 2014-08-28 2016-03-03 Bioatla, Llc Conditionally active chimeric antigen receptors for modified t-cells
GB201415347D0 (en) 2014-08-29 2014-10-15 Ucl Business Plc Signalling system
CN106687584B (en) 2014-09-04 2021-08-13 干细胞技术公司 Soluble antibody complexes for T cell or NK cell activation and expansion
CA2972714A1 (en) 2014-09-09 2016-03-17 Unum Therapeutics Chimeric receptors and uses thereof in immune therapy
UA123764C2 (en) 2014-09-15 2021-06-02 МОЛМЕД СпА Chimeric antigen receptors
EP3193894A1 (en) 2014-09-16 2017-07-26 Fundación Pública Andaluza Progreso Y Salud Use of cord blood plasma to treat nk cell-mediated diseases and ifn- mediated diseases
MA41538A (en) 2014-10-17 2017-12-26 Baylor College Medicine BIPARTITE AND TRIPARTITE IMMUNE CELLS OF SIGNALING
BR112017008696A2 (en) 2014-10-27 2017-12-26 Univ Central Florida Res Found Inc methods and compositions for natural killer cells
WO2016073755A2 (en) 2014-11-05 2016-05-12 Board Of Regents, The University Of Texas System Gene modified immune effector cells and engineered cells for expansion of immune effector cells
IL292450A (en) 2014-11-05 2022-06-01 Juno Therapeutics Inc Methods for transduction and cell processing
ES2806126T3 (en) 2014-11-05 2021-02-16 Univ Texas Chimeric antigen receptors (CARs) selectively target protein complexes
EP3233900A2 (en) 2014-12-19 2017-10-25 Dana-Farber Cancer Institute, Inc. Chimeric antigen receptors and methods of use thereof
JP2018502115A (en) 2014-12-31 2018-01-25 アントフロゲネシス コーポレーション Natural killer cells and uses thereof
US11459390B2 (en) 2015-01-16 2022-10-04 Novartis Ag Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor
MA41433A (en) 2015-01-26 2017-12-05 Baylor College Medicine UNIVERSAL IMMUNE CELLS FOR ANTI-CANCER IMMUNOTHERAPY
US10640570B2 (en) 2015-01-29 2020-05-05 Regents Of The University Of Minnesota Chimeric antigen receptors, compositions, and methods
WO2016126608A1 (en) 2015-02-02 2016-08-11 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
GB201501936D0 (en) 2015-02-05 2015-03-25 Ucl Business Plc Signalling system
US20190024065A1 (en) 2015-02-06 2019-01-24 Cellectis Primary hematopoietic cells genetically engineered by slow release of nucleic acids using nanoparticles
WO2016141357A1 (en) 2015-03-05 2016-09-09 Fred Hutchinson Cancer Research Center Immunomodulatory fusion proteins and uses thereof
US9777064B2 (en) 2015-03-17 2017-10-03 Chimera Bioengineering, Inc. Smart CAR devices, DE CAR polypeptides, side CARs and uses thereof
WO2016154055A1 (en) 2015-03-20 2016-09-29 Bluebird Bio, Inc. Vector formulations
GB201504840D0 (en) 2015-03-23 2015-05-06 Ucl Business Plc Chimeric antigen receptor
WO2016172583A1 (en) 2015-04-23 2016-10-27 Novartis Ag Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
US20180092968A1 (en) 2015-04-23 2018-04-05 The Trustees Of The University Of Pennsylvania Compositions to disrupt protein kinase a anchoring and uses thereof
GB201507119D0 (en) 2015-04-27 2015-06-10 Ucl Business Plc Nucleic Acid Construct
GB201507111D0 (en) 2015-04-27 2015-06-10 Ucl Business Plc Nucleic acid construct
GB201507115D0 (en) 2015-04-27 2015-06-10 Ucl Business Plc Nucleic Acid Construct
GB201507368D0 (en) 2015-04-30 2015-06-17 Ucl Business Plc Cell
WO2016174652A1 (en) 2015-04-30 2016-11-03 Technion Research & Development Foundation Limited Chimeric antigen receptors and methods of their use
WO2016191567A1 (en) 2015-05-26 2016-12-01 Memorial Sloan-Kettering Cancer Center System, method and computer-accessible medium for texture analysis of hepatopancreatobiliary diseases
CN107847583A (en) 2015-05-28 2018-03-27 阿尔莫生物科技股份有限公司 PEGylated Interleukin 10 for treating cancer
BR122023022076A2 (en) 2015-05-28 2024-01-16 Kite Pharma, Inc. PRECONDITIONING AGENTS, THEIR USES AND METHODS FOR IDENTIFYING A DOSE OF ONE OR MORE PRECONDITIONING AGENTS AND FOR VERIFYING THEIR EFFECTIVENESS
AU2016271147B2 (en) 2015-05-29 2022-09-08 Juno Therapeutics, Inc. Composition and methods for regulating inhibitory interactions in genetically engineered cells
WO2016197108A1 (en) 2015-06-05 2016-12-08 Board Of Regents, The University Of Texas System Methods of treatment with natural killer cells matched for killer immunoglobulin receptor type
CN107849112B (en) 2015-06-25 2022-04-01 美商生物细胞基因治疗有限公司 Chimeric Antigen Receptors (CAR), compositions and methods of use thereof
CN108137707A (en) 2015-06-29 2018-06-08 约翰霍普金斯大学 Immunologic test point Chimerical receptor therapy
MA42895A (en) 2015-07-15 2018-05-23 Juno Therapeutics Inc MODIFIED CELLS FOR ADOPTIVE CELL THERAPY
EP3328994A4 (en) 2015-07-31 2019-04-17 Memorial Sloan-Kettering Cancer Center Antigen-binding proteins targeting cd56 and uses thereof
GB201513540D0 (en) 2015-07-31 2015-09-16 King S College London Therapeutic agents
GB201514874D0 (en) 2015-08-20 2015-10-07 Autolus Ltd Cell
AU2016313082B2 (en) 2015-08-24 2022-03-31 Cellectis Chimeric antigen receptors with integrated controllable functions
CN106519037B (en) 2015-09-11 2019-07-23 科济生物医药（上海）有限公司 Activable Chimerical receptor
KR20180051625A (en) 2015-09-17 2018-05-16 노파르티스 아게 CAR T cell therapy with enhanced efficacy
WO2017058752A1 (en) 2015-09-28 2017-04-06 Trustees Of Dartmouth College Chimeric antigen receptor anti-inflammatory cells and methods of use
WO2017058753A1 (en) 2015-09-28 2017-04-06 Trustees Of Dartmouth College Chimeric antigen receptor, regulatory cells and methods of use
MA44314A (en) 2015-11-05 2018-09-12 Juno Therapeutics Inc CHEMERICAL RECEPTORS CONTAINING TRAF-INDUCING DOMAINS, AND ASSOCIATED COMPOSITIONS AND METHODS
AU2017210031C1 (en) 2016-01-20 2020-11-26 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies

Also Published As

Publication number Publication date
US20170107491A1 (en) 2017-04-20
US10538739B2 (en) 2020-01-21
US10774309B2 (en) 2020-09-15
US10801012B2 (en) 2020-10-13
US11873512B2 (en) 2024-01-16
US20180135016A1 (en) 2018-05-17
US20210115404A1 (en) 2021-04-22
EP2948544A4 (en) 2016-08-03
US10829737B2 (en) 2020-11-10
EP2948544A1 (en) 2015-12-02
US10836999B2 (en) 2020-11-17
US20240191196A1 (en) 2024-06-13
US20180135015A1 (en) 2018-05-17
US9511092B2 (en) 2016-12-06
US20160000828A1 (en) 2016-01-07
US20180135014A1 (en) 2018-05-17
WO2014117121A1 (en) 2014-07-31
US20180135013A1 (en) 2018-05-17

Similar Documents

Publication Publication Date Title
SG11201505858VA (en) A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease
IL282741B1 (en) Tazemetostat in combination with a standard care agent for use in the treatment of cancer
HK1214661A1 (en) Facilitating transactions with a user account using a wireless device
SG10202004535PA (en) Enhanced adoptive cell therapy
EP3043819A4 (en) Anti-vstm5 antibodies and the use thereof in therapy and diagnosis
IL246083A0 (en) A checkpoint inhibitor and a whole cell mycobacterium for use in cancer therapy
EP2957270A4 (en) Disposable urine-absorption pad with bedsore-inhibition function
GB201318977D0 (en) Reactor and alkylation process using the reactor
PL2831055T3 (en) Polymerizable alkylidene-1,3-dioxolan-2-ones and use thereof
EP2784843A4 (en) Slurry with improved dispersibility and use therefor
HK1216980A1 (en) Improvements in wheeled suitcases
EP2608630A4 (en) Planar heating body
HK1217964A1 (en) Cushion-like shaped body and use thereof
EP3038182A4 (en) Battery pack having curved surface structure
EP2872973A4 (en) Improvements in devices for use with computers
EP2935215A4 (en) Radiosensitizer compounds for use in combination with radiation
HK1211458A1 (en) Disposable body warmer
EP2808175A4 (en) Erasing implement and writing implement provided with erasing implement
IL238453A0 (en) Trans-clomiphene for use in cancer therapy
EP2836838A4 (en) Methods for determining a breast cancer-associated disease state and arrays for use in the methods
GB201310921D0 (en) Peptide-resin conjugate and use thereof
GB201221227D0 (en) Carbon materials and their use
GB201305940D0 (en) Methods and arrays for use in the same
PL2978521T3 (en) Inclined baseplate in dehydrogenation reactor
GB2520471B (en) Anatomically conforming vaginal insert with cover